| Followers | 35 |
| Posts | 1910 |
| Boards Moderated | 0 |
| Alias Born | 11/05/2020 |
Thursday, June 30, 2022 8:05:40 PM
In the Medical field, the first thing to realize that each product has to pass a number of steps! Even though the patents show that the system works, only through laboriously long clinical trials will be the final proof be established or rejected, which will then be a simple response? Either correct the failed part of the Trial, which will take more time, or send it/them to market upon Clinical Trial approval! We are on the
fast track if I read it right, so we should know before maybe March 2023 on a few of the Compounds/Patents?
He hired his brother to research science he has no qualifications for.
He then hired a contract company ran by Harry Lander to assist in the research who had their website taken down, phone number disconnected and address vacated.
He then took out a toxic loan for $1.5 million. Where did that money go? He defaulted on the loan.
Let that sink in.
The big picture is right in front of people. I'm not Van Gogh. I can't paint the picture for people.
There's a bad joke going around and RGBP investors are the punch line.
Koos came back because of mRNA. He knew what he was doing. He got plain lucky.
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
